Bayer AG stock (DE000BAY0017): pharma focus after aspirin exit and latest Q1 figures

Bayer AG sharpened its focus on prescription drugs and crop science by agreeing to sell its consumer health brands Aspirin and Bepanthen to Haleon, shortly after reporting Q1 2025 results that showed pressure from seed market softness and legacy legal risks.

Bayer AG has moved a step further in reshaping its portfolio: in May 2025 the group agreed to sell its well-known consumer health brands Aspirin and Bepanthen to Haleon for around €8.2 billion, while continuing to prepare a potential separation of its crop science business, according to Bayer press release as of 05/05/2025 and comments around the first-quarter 2025 report published on 30 April 2025, as reported by Reuters as of 04/30/2025.

As of: 18.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Bayer
• Sector/industry: Pharmaceuticals, crop science, consumer health
• Headquarters/country: Leverkusen, Germany
• Core markets: Europe, North America, Latin America, Asia-Pacific
• Key revenue drivers: Prescription medicines, agricultural products
• Home exchange/listing venue: Frankfurt Stock Exchange (ticker: BAYN)
• Trading currency: Euro (EUR)

Bayer AG: core business model

Bayer AG is a diversified life science group with two main pillars: pharmaceuticals and crop science. The company develops and markets prescription medicines in areas such as cardiology, oncology and women’s health, while the agricultural arm focuses on seeds, traits and crop protection products for farmers worldwide, according to the company’s 2024 annual report published on 27 February 2025, as cited by Bayer report as of 02/27/2025.

Historically, Bayer was also known for its consumer health products, including the branded pain reliever Aspirin and the skincare line Bepanthen. The strategy has shifted toward focusing capital and management attention on businesses with higher innovation intensity and potential for scale, especially in pharmaceuticals and agricultural technologies, according to statements from management alongside the 2024 results reported by Reuters as of 02/27/2025.

The group’s pharmaceutical division earns money by developing and commercializing innovative therapies, often in partnership with other biotech firms. Revenue streams include traditional small-molecule drugs and increasingly biologics, which may offer stronger patent protection but require higher R&D and manufacturing investment. Crop science revenue is tied to seed and crop protection sales, often with multi-year product cycles and exposure to weather and commodity market volatility.

Main revenue and product drivers for Bayer AG

In its 2024 annual report, Bayer highlighted that pharmaceuticals and crop science together generated the vast majority of group sales, with consumer health representing a smaller, though historically stable, cash-generating segment, according to Bayer report as of 02/27/2025. Within pharma, key products include cardiovascular and kidney medicines, as well as oncology therapies that have potential for expansion into additional indications and geographies.

Bayer’s crop science division is a leading player in seeds and crop protection, especially in key crops such as corn, soybeans and cotton. Sales in this division depend on planted acreage, product adoption by farmers, competitive pricing and regulatory approvals for new traits or active ingredients. The business also faces seasonal patterns and exposure to changes in agricultural commodity prices, which can influence farm income and investment decisions.

The consumer health division, which includes well-known over-the-counter medicines, has traditionally provided steady cash flows with lower volatility than the more innovation-driven pharmaceutical and crop businesses. The planned sale of Aspirin and Bepanthen to Haleon would reduce Bayer’s exposure to the consumer segment and free up capital. According to the announcement, cash proceeds are expected to be used for debt reduction and to strengthen the balance sheet, according to Bayer press release as of 05/05/2025.

Industry trends and competitive position

Bayer operates in highly competitive and regulated industries. In pharmaceuticals, competitors include large global groups with strong R&D capabilities and significant marketing resources. Competition centers on innovation, clinical trial results, safety profiles and pricing power, especially as healthcare systems in Europe and the United States seek to control costs. Patent expirations can expose established drugs to generic competition, putting pressure on margins, as noted in the 2024 annual filing summarized by Reuters as of 02/27/2025.

In crop science, Bayer faces rivals in seeds and crop protection that are also investing heavily in biotechnology and digital tools for farmers. Regulatory scrutiny over herbicides and pesticides has been intense, especially in the United States and Europe, creating uncertainty about future approvals and potential liabilities. Legal disputes around legacy herbicide products have weighed on investor sentiment and the company’s financial flexibility in recent years.

The planned portfolio reshaping, including the possible spin-off or separation of the crop science division discussed by management in early 2025, is designed to simplify the group’s structure and allow each business to pursue more focused strategies, according to remarks cited by Reuters as of 03/14/2025. How this plays out could influence Bayer’s competitive dynamics and capital allocation priorities over the coming years.

Why Bayer AG matters for US investors

Even though Bayer is headquartered in Germany and listed in Frankfurt, the company has significant operations and revenue exposure in the United States. Its pharmaceuticals are marketed in the US through its own organization and partners, and the crop science division serves American farmers across major agricultural regions. For US-based investors, Bayer represents exposure to global healthcare and agriculture trends through a European blue-chip name, as noted by market commentary in connection with its 2024 results reported by Reuters as of 02/27/2025.

The stock can also be accessed in the United States via over-the-counter listings, and some US-focused funds and ETFs include Bayer as part of their international or healthcare allocations. For US investors, developments in US litigation, regulatory decisions on crop protection products and the performance of the North American farm economy are particularly relevant when evaluating news flow around the company.

Conclusion

Bayer AG is in the midst of a strategic transformation, highlighted by the agreed sale of flagship consumer brands Aspirin and Bepanthen and ongoing deliberations about the future of its crop science division. At the same time, the group continues to manage legacy legal risks and navigate competitive pressures in its pharmaceuticals portfolio. For investors, the stock combines exposure to healthcare innovation and global agriculture with the complexity of major restructuring steps and legal overhangs. How effectively Bayer executes on its portfolio reshaping and maintains growth in core products will likely remain important themes for the market in the coming quarters.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.